Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Search Results

Title:
Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
Protocol Number:
PAALL0932
Phase:
Phase III
Physician:
Patrick Brown
Purpose:
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy), giving the drugs in different doses, and giving the drugs in different combinations may kill more cancer cells. PURPOSE: This partially randomized phase III clinical trial is studying different combinations of risk-adapted chemotherapy regimens and their side effects and comparing how well they work in treating younger patients with newly diagnosed standard-risk acute lymphoblastic leukemia.
Eligibility:
PATIENT CHARACTERISTICS: �WBC count less than 50,000/mm^3 PRIOR CONCURRENT THERAPY: �See Disease Characteristics �No prior cytotoxic chemotherapy for the current diagnosis of ALL or any cancer diagnosed previously oSteroids* and intrathecal cytarabine for the current diagnosis of ALL allowed �Inhalational steroids are not considered as pretreatment See protocol for extensive disease stratification information
Treatment:
Drug: cyclophosphamide Drug: cytarabine Drug: dexamethasone Drug: doxorubicin hydrochloride Drug: leucovorin calcium Drug: mercaptopurine Drug: methotrexate Drug: pegaspargase Drug: thioguanine Drug: vincristine sulfate
Population:
Pediatric
Last Update
08/30/2014 04:02 AM
 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

 

Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424

NCI CCC

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer